Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint and was considered to have failed (Kwon ED, et al. Lancet Oncol 2014 in press). This update included an additional year of data.
In the trial 799 men were randomized to receive a single dose of RT to their bone metastases followed by either Ipi (N = 399) or placebo (N = 400).
An updated overall survival (OS) analys